25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

Dimerix Ltd
Buy, Hold or Sell?

Let's analyze Dimerix together

I guess you are interested in Dimerix Ltd. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Dimerix Ltd. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Dimerix Ltd

I send you an email if I find something interesting about Dimerix Ltd.

1. Quick Overview

1.1. Quick analysis of Dimerix (30 sec.)










1.2. What can you expect buying and holding a share of Dimerix? (30 sec.)

How much money do you get?

How much money do you get?
A$0.05
When do you have the money?
1 year
How often do you get paid?
36.4%

What is your share worth?

Current worth
A$0.01
Expected worth in 1 year
A$-0.05
How sure are you?
63.6%

+ What do you gain per year?

Total Gains per Share
A$0.02
Return On Investment
3.9%

For what price can you sell your share?

Current Price per Share
A$0.42
Expected price per share
A$0.33 - A$0.475
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Dimerix (5 min.)




Live pricePrice per Share (EOD)
A$0.42
Intrinsic Value Per Share
A$-0.32 - A$-0.18
Total Value Per Share
A$-0.31 - A$-0.16

2.2. Growth of Dimerix (5 min.)




Is Dimerix growing?

Current yearPrevious yearGrowGrow %
How rich?$3.9m$9.6m-$5.6m-141.9%

How much money is Dimerix making?

Current yearPrevious yearGrowGrow %
Making money-$9.2m-$7m-$2.2m-24.0%
Net Profit Margin-153.6%-162.3%--

How much money comes from the company's main activities?

2.3. Financial Health of Dimerix (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#716 / 967

Most Revenue
#323 / 967

Most Profit
#551 / 967

Most Efficient
#512 / 967
3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Dimerix?

Welcome investor! Dimerix's management wants to use your money to grow the business. In return you get a share of Dimerix.

First you should know what it really means to hold a share of Dimerix. And how you can make/lose money.

Speculation

The Price per Share of Dimerix is A$0.415. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Dimerix.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Dimerix, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is A$0.01. Based on the TTM, the Book Value Change Per Share is A$-0.02 per quarter. Based on the YOY, the Book Value Change Per Share is A$0.02 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is A$0.02 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Dimerix.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 A$% of Price per ShareA$% of Price per ShareA$% of Price per ShareA$% of Price per ShareA$% of Price per Share
Usd Eps-0.02-4.1%-0.02-4.1%-0.01-3.1%-0.01-2.2%-0.01-1.3%
Usd Book Value Change Per Share-0.01-2.5%-0.01-2.5%0.023.8%0.00-0.1%0.000.1%
Usd Dividend Per Share0.013.1%0.013.1%0.000.0%0.001.2%0.000.5%
Usd Total Gains Per Share0.000.7%0.000.7%0.023.8%0.001.1%0.000.7%
Usd Price Per Share0.04-0.04-0.08-0.11-0.06-
Price to Earnings Ratio-2.47--2.47--6.30--16.95--12.76-
Price-to-Total Gains Ratio15.40-15.40-5.10--0.48-1.94-
Price to Book Ratio5.73-5.73-4.58-23.88-25.21-
Price-to-Total Gains Ratio15.40-15.40-5.10--0.48-1.94-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.278299
Number of shares3593
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.010.00
Usd Book Value Change Per Share-0.010.00
Usd Total Gains Per Share0.000.00
Gains per Quarter (3593 shares)9.7017.07
Gains per Year (3593 shares)38.8068.27
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
1187-1482971-358
2374-29668143-6126
3561-444107214-9194
4747-592146286-13262
5934-740185357-16330
61121-888224428-19398
71308-1036263500-22466
81495-1184302571-25534
91682-1333341643-28602
101869-1481380714-31670

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.01.00.00.0%0.03.00.00.0%0.05.00.00.0%0.011.00.00.0%4.032.00.011.1%
Book Value Change Per Share0.01.00.00.0%1.02.00.033.3%2.03.00.040.0%6.05.00.054.5%18.018.00.050.0%
Dividend per Share1.00.00.0100.0%3.00.00.0100.0%4.00.01.080.0%4.00.07.036.4%8.00.028.022.2%
Total Gains per Share1.00.00.0100.0%2.01.00.066.7%3.02.00.060.0%7.04.00.063.6%19.017.00.052.8%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Dimerix Ltd compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.015-0.0150%0.024-165%0.000-98%0.001-2286%
Book Value Per Share--0.0110.0110%0.026-59%0.012-12%0.008+32%
Current Ratio--1.5101.5100%8.148-81%4.297-65%10.162-85%
Debt To Asset Ratio--0.6640.6640%0.126+428%0.407+63%0.306+117%
Debt To Equity Ratio--1.9781.9780%0.144+1275%1.610+23%5.807-66%
Dividend Per Share--0.0190.0190%0.000+763581%0.007+162%0.003+476%
Eps---0.025-0.0250%-0.019-24%-0.014-45%-0.008-67%
Free Cash Flow Per Share---0.023-0.0230%-0.024+6%-0.015-37%-0.009-63%
Free Cash Flow To Equity Per Share---0.003-0.0030%0.008-139%0.004-180%0.003-215%
Gross Profit Margin--1.0011.0010%1.0030%1.027-3%1.031-3%
Intrinsic Value_10Y_max---0.175--------
Intrinsic Value_10Y_min---0.325--------
Intrinsic Value_1Y_max---0.011--------
Intrinsic Value_1Y_min---0.023--------
Intrinsic Value_3Y_max---0.037--------
Intrinsic Value_3Y_min---0.078--------
Intrinsic Value_5Y_max---0.070--------
Intrinsic Value_5Y_min---0.142--------
Market Cap228525135.040+85%34141104.51234141104.5120%66079557.120-48%89427667.302-62%47517208.802-28%
Net Profit Margin---1.536-1.5360%-1.623+6%-1.702+11%-3.688+140%
Operating Margin---2.541-2.5410%-2.623+3%-2.715+7%-3.930+55%
Operating Ratio--2.5412.5410%2.623-3%2.715-6%4.274-41%
Pb Ratio38.323+85%5.7255.7250%4.582+25%23.881-76%25.206-77%
Pe Ratio-16.556-569%-2.473-2.4730%-6.299+155%-16.945+585%-12.757+416%
Price Per Share0.415+85%0.0620.0620%0.120-48%0.162-62%0.086-28%
Price To Free Cash Flow Ratio-17.948-569%-2.681-2.6810%-4.914+83%-16.396+511%-10.962+309%
Price To Total Gains Ratio103.091+85%15.40215.4020%5.100+202%-0.475+103%1.942+693%
Quick Ratio--1.4921.4920%7.914-81%4.205-65%9.949-85%
Return On Assets---0.777-0.7770%-0.636-18%-0.621-20%-0.640-18%
Return On Equity---2.315-2.3150%-0.727-69%-1.729-25%-1.794-23%
Total Gains Per Share--0.0040.0040%0.024-83%0.007-43%0.004-1%
Usd Book Value--3998867.6013998867.6010%9671822.384-59%4535455.434-12%3019777.031+32%
Usd Book Value Change Per Share---0.010-0.0100%0.016-165%0.000-98%0.000-2286%
Usd Book Value Per Share--0.0070.0070%0.018-59%0.008-12%0.005+32%
Usd Dividend Per Share--0.0130.0130%0.000+763581%0.005+162%0.002+476%
Usd Eps---0.017-0.0170%-0.013-24%-0.009-45%-0.006-67%
Usd Free Cash Flow---8538617.692-8538617.6920%-9017257.101+6%-5382355.235-37%-2910482.155-66%
Usd Free Cash Flow Per Share---0.016-0.0160%-0.016+6%-0.010-37%-0.006-63%
Usd Free Cash Flow To Equity Per Share---0.002-0.0020%0.005-139%0.003-180%0.002-215%
Usd Market Cap153248955.558+85%22895024.68622895024.6860%44312951.005-48%59970193.693-62%31865040.222-28%
Usd Price Per Share0.278+85%0.0420.0420%0.080-48%0.109-62%0.058-28%
Usd Profit---9256170.421-9256170.4210%-7034982.277-24%-5102663.265-45%-3036052.249-67%
Usd Revenue--6024494.0326024494.0320%4334392.923+39%3175324.664+90%1604239.741+276%
Usd Total Gains Per Share--0.0030.0030%0.016-83%0.005-43%0.003-1%
 EOD+6 -2MRQTTM+0 -0YOY+11 -255Y+9 -2710Y+13 -23

3.3 Fundamental Score

Let's check the fundamental score of Dimerix Ltd based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-16.556
Price to Book Ratio (EOD)Between0-138.323
Net Profit Margin (MRQ)Greater than0-1.536
Operating Margin (MRQ)Greater than0-2.541
Quick Ratio (MRQ)Greater than11.492
Current Ratio (MRQ)Greater than11.510
Debt to Asset Ratio (MRQ)Less than10.664
Debt to Equity Ratio (MRQ)Less than11.978
Return on Equity (MRQ)Greater than0.15-2.315
Return on Assets (MRQ)Greater than0.05-0.777
Total3/10 (30.0%)

3.4 Technical Score

Let's check the technical score of Dimerix Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5046.987
Ma 20Greater thanMa 500.426
Ma 50Greater thanMa 1000.447
Ma 100Greater thanMa 2000.446
OpenGreater thanClose0.435
Total3/5 (60.0%)

4. In-depth Analysis

4.1 About Dimerix Ltd

Dimerix Limited, a biopharmaceutical company, develops and commercializes pharmaceutical products for unmet medical needs. It develops DMX-200, a Phase 3 clinical trial for focal segmental glomerulosclerosis disease; DMX-200 for diabetic kidney disease; and DMX-700 for chronic obstructive pulmonary disease, as well as develops proprietary receptor- HIT assay technology. The company is headquartered in Fitzroy, Australia.

Fundamental data was last updated by Penke on 2024-08-31 08:05:05.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is able to pay all its debts by selling its assets.
The company is just able to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is overpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Dimerix earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Dimerix to the Biotechnology industry mean.
  • A Net Profit Margin of -153.6% means that $-1.54 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Dimerix Ltd:

  • The MRQ is -153.6%. The company is making a huge loss. -2
  • The TTM is -153.6%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-153.6%TTM-153.6%0.0%
TTM-153.6%YOY-162.3%+8.7%
TTM-153.6%5Y-170.2%+16.5%
5Y-170.2%10Y-368.8%+198.6%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-153.6%-132.1%-21.5%
TTM-153.6%-212.2%+58.6%
YOY-162.3%-221.9%+59.6%
5Y-170.2%-373.2%+203.0%
10Y-368.8%-490.1%+121.3%
4.3.1.2. Return on Assets

Shows how efficient Dimerix is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Dimerix to the Biotechnology industry mean.
  • -77.7% Return on Assets means that Dimerix generated $-0.78 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Dimerix Ltd:

  • The MRQ is -77.7%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -77.7%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-77.7%TTM-77.7%0.0%
TTM-77.7%YOY-63.6%-14.1%
TTM-77.7%5Y-62.1%-15.6%
5Y-62.1%10Y-64.0%+1.9%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-77.7%-11.1%-66.6%
TTM-77.7%-11.7%-66.0%
YOY-63.6%-11.2%-52.4%
5Y-62.1%-12.9%-49.2%
10Y-64.0%-14.4%-49.6%
4.3.1.3. Return on Equity

Shows how efficient Dimerix is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Dimerix to the Biotechnology industry mean.
  • -231.5% Return on Equity means Dimerix generated $-2.31 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Dimerix Ltd:

  • The MRQ is -231.5%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -231.5%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-231.5%TTM-231.5%0.0%
TTM-231.5%YOY-72.7%-158.7%
TTM-231.5%5Y-172.9%-58.5%
5Y-172.9%10Y-179.4%+6.4%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-231.5%-13.6%-217.9%
TTM-231.5%-16.1%-215.4%
YOY-72.7%-13.6%-59.1%
5Y-172.9%-18.9%-154.0%
10Y-179.4%-19.1%-160.3%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Dimerix Ltd.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Dimerix is operating .

  • Measures how much profit Dimerix makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Dimerix to the Biotechnology industry mean.
  • An Operating Margin of -254.1% means the company generated $-2.54  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Dimerix Ltd:

  • The MRQ is -254.1%. The company is operating very inefficient. -2
  • The TTM is -254.1%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-254.1%TTM-254.1%0.0%
TTM-254.1%YOY-262.3%+8.3%
TTM-254.1%5Y-271.5%+17.4%
5Y-271.5%10Y-393.0%+121.5%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-254.1%-277.8%+23.7%
TTM-254.1%-279.2%+25.1%
YOY-262.3%-234.1%-28.2%
5Y-271.5%-388.9%+117.4%
10Y-393.0%-496.6%+103.6%
4.3.2.2. Operating Ratio

Measures how efficient Dimerix is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 2.54 means that the operating costs are $2.54 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Dimerix Ltd:

  • The MRQ is 2.541. The company is inefficient in keeping operating costs low. -1
  • The TTM is 2.541. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ2.541TTM2.5410.000
TTM2.541YOY2.623-0.083
TTM2.5415Y2.715-0.174
5Y2.71510Y4.274-1.559
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ2.5412.761-0.220
TTM2.5413.321-0.780
YOY2.6233.430-0.807
5Y2.7155.021-2.306
10Y4.2746.570-2.296
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Dimerix Ltd.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Dimerix is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 1.51 means the company has $1.51 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Dimerix Ltd:

  • The MRQ is 1.510. The company is able to pay all its short-term debts. +1
  • The TTM is 1.510. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ1.510TTM1.5100.000
TTM1.510YOY8.148-6.638
TTM1.5105Y4.297-2.787
5Y4.29710Y10.162-5.865
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.5103.734-2.224
TTM1.5103.909-2.399
YOY8.1484.740+3.408
5Y4.2975.955-1.658
10Y10.1626.303+3.859
4.4.3.2. Quick Ratio

Measures if Dimerix is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Dimerix to the Biotechnology industry mean.
  • A Quick Ratio of 1.49 means the company can pay off $1.49 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Dimerix Ltd:

  • The MRQ is 1.492. The company is able to pay all its short-term debts with the most liquid assets. +1
  • The TTM is 1.492. The company is able to pay all its short-term debts with the most liquid assets. +1
Trends
Current periodCompared to+/- 
MRQ1.492TTM1.4920.000
TTM1.492YOY7.914-6.421
TTM1.4925Y4.205-2.713
5Y4.20510Y9.949-5.744
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.4923.134-1.642
TTM1.4923.444-1.952
YOY7.9144.693+3.221
5Y4.2055.867-1.662
10Y9.9496.479+3.470
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Dimerix Ltd.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Dimerix assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Dimerix to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.66 means that Dimerix assets are financed with 66.4% credit (debt) and the remaining percentage (100% - 66.4%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Dimerix Ltd:

  • The MRQ is 0.664. The company is able to pay all its debts by selling its assets. +1
  • The TTM is 0.664. The company is able to pay all its debts by selling its assets. +1
Trends
Current periodCompared to+/- 
MRQ0.664TTM0.6640.000
TTM0.664YOY0.126+0.538
TTM0.6645Y0.407+0.257
5Y0.40710Y0.306+0.101
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.6640.343+0.321
TTM0.6640.346+0.318
YOY0.1260.306-0.180
5Y0.4070.365+0.042
10Y0.3060.382-0.076
4.5.4.2. Debt to Equity Ratio

Measures if Dimerix is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Dimerix to the Biotechnology industry mean.
  • A Debt to Equity ratio of 197.8% means that company has $1.98 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Dimerix Ltd:

  • The MRQ is 1.978. The company is just able to pay all its debts with equity.
  • The TTM is 1.978. The company is just able to pay all its debts with equity.
Trends
Current periodCompared to+/- 
MRQ1.978TTM1.9780.000
TTM1.978YOY0.144+1.834
TTM1.9785Y1.610+0.368
5Y1.61010Y5.807-4.197
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ1.9780.395+1.583
TTM1.9780.450+1.528
YOY0.1440.372-0.228
5Y1.6100.449+1.161
10Y5.8070.488+5.319
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Dimerix generates.

  • Above 15 is considered overpriced but always compare Dimerix to the Biotechnology industry mean.
  • A PE ratio of -2.47 means the investor is paying $-2.47 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Dimerix Ltd:

  • The EOD is -16.556. Based on the earnings, the company is expensive. -2
  • The MRQ is -2.473. Based on the earnings, the company is expensive. -2
  • The TTM is -2.473. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-16.556MRQ-2.473-14.083
MRQ-2.473TTM-2.4730.000
TTM-2.473YOY-6.299+3.825
TTM-2.4735Y-16.945+14.472
5Y-16.94510Y-12.757-4.188
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-16.556-2.335-14.221
MRQ-2.473-2.413-0.060
TTM-2.473-2.978+0.505
YOY-6.299-3.462-2.837
5Y-16.945-6.080-10.865
10Y-12.757-6.254-6.503
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Dimerix Ltd:

  • The EOD is -17.948. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -2.681. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -2.681. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-17.948MRQ-2.681-15.266
MRQ-2.681TTM-2.6810.000
TTM-2.681YOY-4.914+2.233
TTM-2.6815Y-16.396+13.714
5Y-16.39610Y-10.962-5.434
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-17.948-3.054-14.894
MRQ-2.681-3.229+0.548
TTM-2.681-3.575+0.894
YOY-4.914-4.723-0.191
5Y-16.396-8.076-8.320
10Y-10.962-8.636-2.326
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Dimerix is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 5.73 means the investor is paying $5.73 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Dimerix Ltd:

  • The EOD is 38.323. Based on the equity, the company is expensive. -2
  • The MRQ is 5.725. Based on the equity, the company is overpriced. -1
  • The TTM is 5.725. Based on the equity, the company is overpriced. -1
Trends
Current periodCompared to+/- 
EOD38.323MRQ5.725+32.598
MRQ5.725TTM5.7250.000
TTM5.725YOY4.582+1.144
TTM5.7255Y23.881-18.156
5Y23.88110Y25.206-1.325
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD38.3231.829+36.494
MRQ5.7251.903+3.822
TTM5.7252.225+3.500
YOY4.5822.412+2.170
5Y23.8813.546+20.335
10Y25.2064.109+21.097
4.6.2. Total Gains per Share

4.7 Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Dimerix Ltd.

3rd party ad coffee SUPPORTERis ad-free.

5. Financial Statements




5.1. Latest Balance Sheet

Balance Sheet of 2023-06-30. Currency in AUD. All numbers in thousands.

Summary
Total Assets17,758
Total Liabilities11,794
Total Stockholder Equity5,963
 As reported
Total Liabilities 11,794
Total Stockholder Equity+ 5,963
Total Assets = 17,758

Assets

Total Assets17,758
Total Current Assets17,751
Long-term Assets6
Total Current Assets
Cash And Cash Equivalents 7,992
Net Receivables 9,554
Other Current Assets 206
Total Current Assets  (as reported)17,751
Total Current Assets  (calculated)17,751
+/-0
Long-term Assets
Property Plant Equipment 6
Long-term Assets  (as reported)6
Long-term Assets  (calculated)6
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities11,756
Long-term Liabilities38
Total Stockholder Equity5,963
Total Current Liabilities
Short-term Debt 5,958
Short Long Term Debt 5,936
Accounts payable 5,137
Other Current Liabilities 661
Total Current Liabilities  (as reported)11,756
Total Current Liabilities  (calculated)17,692
+/- 5,936
Long-term Liabilities
Other Liabilities 38
Long-term Liabilities  (as reported)38
Long-term Liabilities  (calculated)38
+/-0
Total Stockholder Equity
Common Stock55,489
Retained Earnings -52,101
Accumulated Other Comprehensive Income 2,575
Total Stockholder Equity (as reported)5,963
Total Stockholder Equity (calculated)5,963
+/-0
Other
Capital Stock55,489
Cash And Equivalents7,992
Cash and Short Term Investments 7,992
Common Stock Shares Outstanding 325,529
Current Deferred Revenue-5,958
Liabilities and Stockholders Equity 17,758
Net Debt -2,034
Net Invested Capital 11,899
Net Tangible Assets 5,963
Net Working Capital 5,995
Property Plant and Equipment Gross 40
Short Long Term Debt Total 5,958



5.2. Balance Sheets Structured

Currency in AUD. All numbers in thousands.

 Trend2023-06-302022-06-302021-06-302020-06-302019-06-302018-06-302017-06-302016-06-302015-06-302014-06-302014-04-302013-06-302012-06-302011-06-302010-06-302009-06-302008-06-302007-06-302006-06-302005-06-302004-06-302003-06-302002-06-302001-06-302000-06-301999-06-301998-06-301997-06-301996-06-301995-06-301994-06-301993-06-301992-06-301991-06-301990-06-301989-06-30
> Total Assets 
1,781
1,727
1,149
1,161
1,636
2,033
1,981
2,244
2,261
9,690
9,121
7,902
2,278
1,891
1,216
1,828
10,521
3,038
4,072
2,449
385
1,607
1,594
1,214
1,753
1,762
1,214
2,969
2,525
2,872
7,265
4,941
10,389
9,421
16,497
17,758
17,75816,4979,42110,3894,9417,2652,8722,5252,9691,2141,7621,7531,2141,5941,6073852,4494,0723,03810,5211,8281,2161,8912,2787,9029,1219,6902,2612,2441,9812,0331,6361,1611,1491,7271,781
   > Total Current Assets 
387
240
246
267
88
104
62
187
207
4,577
3,115
2,448
1,513
1,145
625
1,388
2,405
1,166
730
599
383
1,178
1,594
1,214
1,753
1,759
1,214
2,964
2,523
2,869
7,264
4,938
10,388
9,419
16,488
17,751
17,75116,4889,41910,3884,9387,2642,8692,5232,9641,2141,7591,7531,2141,5941,1783835997301,1662,4051,3886251,1451,5132,4483,1154,5772071876210488267246240387
       Cash And Cash Equivalents 
21
10
8
213
30
80
47
173
82
1,280
87
17
245
42
51
136
2,236
1,134
446
118
372
1,164
1,032
154
1,153
1,673
1,199
2,931
2,019
2,245
6,284
3,563
7,786
5,250
9,630
7,992
7,9929,6305,2507,7863,5636,2842,2452,0192,9311,1991,6731,1531541,0321,1643721184461,1342,236136514224517871,2808217347803021381021
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
300
0
0
0
0
0
0
0
0
424
1,030
594
0
0
0
0
0
0
0
0
0
0
0
000000000005941,030424000000003000000000000000
       Net Receivables 
366
230
238
54
58
24
15
14
125
2,105
1,460
1,464
809
551
323
401
169
32
147
119
11
14
138
30
7
86
3
21
459
577
903
1,275
2,464
4,008
6,385
9,554
9,5546,3854,0082,4641,275903577459213867301381411119147321694013235518091,4641,4602,1051251415245854238230366
       Other Current Assets 
0
0
0
0
0
0
0
0
60
0
1
0
4
300
0
119
0
0
54
191
0
0
15
15
0
0
11
11
504
624
980
1,375
138
161
474
206
2064741611381,3759806245041111001515001915400119030040106000000000
   > Long-term Assets 
1,394
1,487
903
894
1,548
1,929
1,919
2,057
2,054
5,113
6,007
5,454
765
746
592
440
8,116
1,872
3,341
1,849
3
429
0
0
0
0
3
5
2
3
0
3
1
1
9
6
6911303253000042931,8493,3411,8728,1164405927467655,4546,0075,1132,0542,0571,9191,9291,5488949031,4871,394
       Property Plant Equipment 
803
896
880
870
1,548
1,929
1,919
2,057
2,054
2,675
3,631
3,456
765
626
209
531
5
23
17
17
3
0
0
0
0
3
3
5
2
3
0
3
1
1
9
6
691130325330000317172355312096267653,4563,6312,6752,0542,0571,9191,9291,548870880896803
       Goodwill 
0
0
0
0
0
0
0
0
0
2,224
2,111
1,998
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000000001,9982,1112,224000000000
       Intangible Assets 
0
0
0
0
0
0
0
0
0
2,225
2,111
1,998
0
47
38
13
8,110
0
3,324
1,832
0
0
0
11,962
0
0
0
0
0
0
0
0
0
0
0
0
00000000000011,9620001,8323,32408,11013384701,9982,1112,225000000000
       Long-term Assets Other 
591
591
0
0
0
0
0
0
0
213
265
0
0
322
336
339
0
0
0
0
0
0
0
0
0
0
-3
0
-2
-3
0
-3
-1
-1
-9
-6
-6-9-1-1-30-3-20-30000000000339336322002652130000000591591
> Total Liabilities 
256
318
103
117
226
292
257
394
303
4,664
3,350
2,661
1,638
1,608
1,781
1,998
240
344
2,657
1,440
43
46
28
35
46
1,731
34
192
283
242
407
738
2,630
7,952
2,074
11,794
11,7942,0747,9522,630738407242283192341,73146352846431,4402,6573442401,9981,7811,6081,6382,6613,3504,664303394257292226117103318256
   > Total Current Liabilities 
26
74
80
103
83
96
61
228
167
3,179
3,082
2,390
1,595
1,320
1,232
1,190
240
344
1,498
1,440
43
46
28
35
46
1,731
34
192
283
242
407
738
2,630
7,952
2,024
11,756
11,7562,0247,9522,630738407242283192341,73146352846431,4401,4983442401,1901,2321,3201,5952,3903,0823,179167228619683103807426
       Short-term Debt 
0
6
8
10
2
0
0
166
34
1,361
1,839
1,377
75
216
11
10
10
10
951
1,018
0
0
424
1,030
594
0
0
0
0
0
0
1,094
1,055
5,043
52
5,958
5,958525,0431,0551,0940000005941,030424001,01895110101011216751,3771,8391,3613416600210860
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,063
5,050
0
5,936
5,93605,0501,06300000000000000000000000000000000
       Accounts payable 
20
67
48
76
23
30
21
17
96
881
825
1,079
1,331
986
1,142
1,110
81
266
470
422
22
46
28
35
6
103
2
136
133
83
269
417
1,149
2,520
1,111
5,137
5,1371,1112,5201,149417269831331362103635284622422470266811,1101,1429861,3311,079825881961721302376486720
       Other Current Liabilities 
6
7
32
27
24
30
5
9
0
2,361
2,567
1,852
606
11
630
523
149
68
169
80
21
12
9
11
41
1,628
32
56
149
159
137
321
425
389
861
661
66186138942532113715914956321,6284111912218016968149523630116061,8522,5672,3610953024273276
   > Long-term Liabilities 
230
244
23
14
143
196
196
166
136
1,485
268
272
42
288
549
808
0
0
1,159
0
0
0
0
0
0
0
0
0
0
0
0
417
2,243
51
51
38
3851512,2434170000000000001,15900808549288422722681,4851361661961961431423244230
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
21
0
0210000000000000000000000000000000000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
25
26
23
23
24
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
30
38
3830000000000000000000242323262500000000000
> Total Stockholder Equity
1,525
1,409
1,046
1,044
1,410
1,741
1,724
1,850
1,958
5,026
5,772
5,240
640
283
-565
-170
10,281
2,694
1,415
1,008
342
1,560
1,566
1,180
1,707
31
1,179
2,777
2,243
2,630
6,858
4,203
7,759
1,468
14,423
5,963
5,96314,4231,4687,7594,2036,8582,6302,2432,7771,179311,7071,1801,5661,5603421,0081,4152,69410,281-170-5652836405,2405,7725,0261,9581,8501,7241,7411,4101,0441,0461,4091,525
   Common Stock
756
756
756
756
830
914
1,029
1,140
1,394
2,557
4,713
4,714
4,713
5,144
5,292
6,389
17,436
20,244
21,300
24,332
27,834
29,400
29,400
29,400
30,286
3,038
30,286
31,558
10,920
13,013
20,287
20,475
28,344
28,389
50,895
55,489
55,48950,89528,38928,34420,47520,28713,01310,92031,55830,2863,03830,28629,40029,40029,40027,83424,33221,30020,24417,4366,3895,2925,1444,7134,7144,7132,5571,3941,1401,029914830756756756756
   Retained Earnings 
588
469
125
124
59
-78
-201
-325
-465
-254
92
-424
-4,108
-4,974
-5,943
-6,619
-7,155
-18,316
-20,126
-23,504
-27,552
-27,862
-27,857
-28,220
-28,737
-3,007
-29,265
-29,945
-8,977
-10,736
-14,055
-16,942
-21,436
-27,808
-38,298
-52,101
-52,101-38,298-27,808-21,436-16,942-14,055-10,736-8,977-29,945-29,265-3,007-28,737-28,220-27,857-27,862-27,552-23,504-20,126-18,316-7,155-6,619-5,943-4,974-4,108-42492-254-465-325-201-7859124125469588
   Capital Surplus 000000000000000000000000000000000000
   Treasury Stock000000000000000000000000000000000000
   Other Stockholders Equity 
181
184
165
193
532
918
910
1,048
0
1
-1,734
-1
-150
-42
0
0
7
0
0
152
0
0
0
0
-2,818
0
0
0
300
353
626
670
-6,908
-582
-12,597
-3,388
-3,388-12,597-582-6,908670626353300000-2,818000015200700-42-150-1-1,734101,048910918532193165184181



5.3. Balance Sheets

Currency in AUD. All numbers in thousands.